2019
Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi‐centre cohort
Bajaj JS, O’Leary J, Tandon P, Wong F, Kamath PS, Biggins SW, Garcia‐Tsao G, Lai J, Fallon MB, Thuluvath PJ, Vargas HE, Maliakkal B, Subramanian RM, Thacker LR, Reddy KR. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi‐centre cohort. Alimentary Pharmacology & Therapeutics 2019, 49: 1518-1527. PMID: 31032966, PMCID: PMC6538445, DOI: 10.1111/apt.15265.Peer-Reviewed Original ResearchConceptsQuality of careAspiration pneumoniaEnd-stage Liver Disease cohortLiver disease cohortMulti-center cohortNorth American ConsortiumLiver transplantMELD scoreCirrhotic patientsDual therapyHepatic encephalopathyPneumonia developmentReadmission analysisBetter prognosisPatient cohortTherapy patientsDisease cohortLarge cohortPatientsMedicationsCohortAmerican ConsortiumTherapyReadmissionPneumonia
2018
Cirrhosis and Portal Hypertension: Staging and Prognosis
Garcia-Tsao G. Cirrhosis and Portal Hypertension: Staging and Prognosis. 2018, 1-13. DOI: 10.1007/978-3-319-72628-1_1.Peer-Reviewed Educational MaterialsSignificant portal hypertensionPortal hypertensionDecompensated stagePredominant pathophysiological mechanismPresence of varicesGastroesophageal varicesPrognostic significanceReversible diseasePathophysiological mechanismsDifferent therapiesHypertensionVaricesCirrhosisDecompensationPatientsTherapyDisease
2017
Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta‐analysis
Albillos A, Zamora J, Martínez J, Arroyo D, Ahmad I, De‐la‐Peña J, Garcia‐Pagán J, Lo G, Sarin S, Sharma B, Abraldes JG, Bosch J, Garcia‐Tsao G, Cooperation O. Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta‐analysis. Hepatology 2017, 66: 1219-1231. PMID: 28543862, PMCID: PMC5605404, DOI: 10.1002/hep.29267.Peer-Reviewed Original ResearchConceptsChild B/CPrevious variceal bleedingCombination therapyVariceal bleedingCirrhosis severityChild APrognostic stageRecurrent variceal hemorrhageAdvanced liver failureEndoscopic variceal ligationOutcome of therapyVariceal hemorrhageLiver failureVariceal ligationLiver functionPatientsPatient careVaricealTherapyPatient dataMortalityTrialsCirrhosisBleedingProphylaxisTHU-209 In hepatitis C virus-related advanced fibrosis and cirrhosis, early decline of liver stiffness following antiviral therapy with DAAs is related to decline in liver inflammation
Winters A, Luedtke S, Moreland A, Jangouk P, Weng G, Silveira M, Davitkov P, Duarte-Rojo A, Cheung R, Garcia-Tsao G, Falck-Ytter Y, Branch A, Bräu N. THU-209 In hepatitis C virus-related advanced fibrosis and cirrhosis, early decline of liver stiffness following antiviral therapy with DAAs is related to decline in liver inflammation. Journal Of Hepatology 2017, 66: s280. DOI: 10.1016/s0168-8278(17)30876-0.Peer-Reviewed Original ResearchChapter 36 Ascites
Garcia-Tsao G. Chapter 36 Ascites. 2017, 475-484. DOI: 10.1016/b978-0-12-804274-8.00036-9.Peer-Reviewed Educational MaterialsRefractory ascitesCommon decompensating eventNew-onset ascitesSodium-retaining systemsFirst-line therapyDevelopment of ascitesCause of deathPortal hypertensionRenal failureSodium retentionPathophysiological mechanismsOvert infectionAscitesPathogenic cascadeHigh mortalityVasodilatationEarly placementPatientsCirrhosisDeathHypertensionTherapyInfectionMortality
2016
Introduction and Survey Results
Garcia-Tsao G, Ripoll C, Augustin S, Reiberger T, Albillos A, Moreau R, Salerno F, Abraldes J. Introduction and Survey Results. 2016, 303-309. DOI: 10.1007/978-3-319-23018-4_30.Peer-Reviewed Original ResearchComplications of cirrhosisRecurrent variceal hemorrhageVariceal hemorrhageDifferent prognostic stagesEndpoints of trialsPresence of varicesInvestigation of patientsCompensated patientsCurrent therapiesSpecific therapyDifferent prognosisPrognostic stageHemorrhageCirrhosisPatientsComplicationsTherapyDifferent efficacyVaricesDecompensationPrognosisRecurrencePrevention of Variceal Rebleeding: Stratifying Risk and Individualizing Care
Albillos A, Abraldes J, Ripoll C, Reiberger T, Augustin S, Salerno F, Moreau R, Garcia-Tsao G. Prevention of Variceal Rebleeding: Stratifying Risk and Individualizing Care. 2016, 311-316. DOI: 10.1007/978-3-319-23018-4_31.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsStandard of careCombination therapyVariceal rebleedingVariceal ligationChild AChild B/C patientsChild B/CSecond-line therapyStandard combination therapyIndividual patient dataLow rebleedingVariceal bleedC patientsPortal hypertensionCirrhotic patientsLine therapyRisk stratificationTailor therapySuch therapyTherapyRebleedingPatientsPatient dataCarePrevention
2012
Sa1091 Hepatitis C (HCV) Antiviral Therapy is Feasible in Patients With Active Substance use (SU) and Mental Illness (MI) and is More Likely to Occur in Those Who Receive Education Class
Bari K, Augustin S, Eggers C, Hashem H, Desai M, Shea M, Wongcharatrawee S, Lim J, Garcia-Tsao G. Sa1091 Hepatitis C (HCV) Antiviral Therapy is Feasible in Patients With Active Substance use (SU) and Mental Illness (MI) and is More Likely to Occur in Those Who Receive Education Class. Gastroenterology 2012, 142: s-967. DOI: 10.1016/s0016-5085(12)63744-5.Peer-Reviewed Original Research
2009
Pharmacological versus endoscopic therapy in the prevention of variceal hemorrhage: And the winner is…
Bosch J, Garcia‐Tsao G. Pharmacological versus endoscopic therapy in the prevention of variceal hemorrhage: And the winner is…. Hepatology 2009, 50: 674-677. PMID: 19714716, DOI: 10.1002/hep.23164.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2006
Liver involvement in hereditary hemorrhagic telangiectasia: consensus recommendations
Buscarini E, Plauchu H, Tsao G, White RI, Sabbà C, Miller F, Saurin JC, Pelage JP, Lesca G, Marion MJ, Perna A, Faughnan ME. Liver involvement in hereditary hemorrhagic telangiectasia: consensus recommendations. Liver International 2006, 26: 1040-1046. PMID: 17032403, DOI: 10.1111/j.1478-3231.2006.01340.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHereditary hemorrhagic telangiectasiaLiver involvementHemorrhagic telangiectasiaIntensive medical therapyFormal consensus development processMinority of patientsFirst-line imagingFocal nodular hyperplasiaConsensus development processHHT populationLiver biopsyMedical therapyClinical managementNodular hyperplasiaConsensus statementConsensus recommendationsInvasive therapyDoppler USGeneral populationNominal group techniquePatientsTherapeutic issuesMedian scoreTherapyInvolvement
2002
Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?
Burroughs A, Groszmann R, Bosch J, Grace N, Garcia-Tsao G, Patch D, Garcia-Pagan J, Dagher L. Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? Gut 2002, 50: 425. PMID: 11839726, PMCID: PMC1773121, DOI: 10.1136/gut.50.3.425.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientChronic hepatitis CVenous pressure gradientHepatitis CAntiviral therapyEnd pointChronic hepatitis C.Major healthcare problemBest end pointHepatitis C.HVPG measurementTherapeutic benefitTherapeutic evaluationTherapyHealthcare problemPatientsPressure gradientResponse
2001
CLINICAL MANAGEMENT OF ASCITES AND ITS COMPLICATIONS
Wongcharatrawee S, Garcia-Tsao G. CLINICAL MANAGEMENT OF ASCITES AND ITS COMPLICATIONS. Clinics In Liver Disease 2001, 5: 833-850. PMID: 11565143, DOI: 10.1016/s1089-3261(05)70194-x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsEffective arterial blood volumeElimination of ascitesTherapy of ascitesPoor prognostic signYear mortality rateDevelopment of ascitesArterial blood volumeQuality of lifeSinusoidal hypertensionLiver transplantationCirrhotic patientsSurvival benefitLethal complicationPathophysiologic abnormalitiesPrognostic signSodium retentionCurrent therapiesAscites formationClinical managementAscitesBlood volumeMortality rateComplicationsTherapyHypertension
1999
Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: A caution
García–Tsao G. Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: A caution. Gastroenterology 1999, 117: 740-741. PMID: 10464155, DOI: 10.1016/s0016-5085(99)70472-5.Commentaries, Editorials and Letters
1995
Variceal Hemorrhage
Navarro V, Garcia-Tsao G. Variceal Hemorrhage. Critical Care Clinics 1995, 11: 391-414. PMID: 7788538, DOI: 10.1016/s0749-0704(18)30073-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsVariceal bleedingVariceal hemorrhageFirst variceal bleedingHigh recurrence ratePortal hypertensionBalloon tamponadePharmacologic therapyPortal pressureShunt surgeryActive hemorrhageRecurrence rateBlood flowTherapeutic avenuesHigh mortalityHemorrhageBleedingPreventionHypertensionTamponadeSclerotherapyComplicationsSurgeryRelative effectivenessTherapyMortality